Section 54
Chapter 53,518

Hepatitis C virus (HCV) -specific T-cell responses among recombinant immunoblot assay-3-indeterminate blood donors: a confirmatory evidence of HCV exposure

Bes, M.; Esteban, J.I.; Casamitjana, N.àl.; Piron, M.; Quer, J.; Cubero, M.ía.; Puig, L.ís.; Guardia, J.; Sauleda, S.íl.

Transfusion 49(7): 1296-1305


ISSN/ISBN: 1537-2995
PMID: 19222816
DOI: 10.1111/j.1537-2995.2009.02103.x
Accession: 053517429

Download citation:  

Blood donors are routinely screened for hepatitis C virus (HCV) infection. Some show weak anti-HCV responses, often restricted to a single antigen on confirmatory immunoblot (recombinant immunoblot assay [RIBA]) testing. The aim of this study was to investigate the extent to which such RIBA-indeterminate donors had previously been exposed to HCV. T-cell responses to HCV recombinant proteins (core, NS3, and NS3 helicase) were analyzed using an interferon-gamma (IFN-gamma) enzyme-linked immunospot (ELISpot) assay and quantification of cytokines in culture supernatants in 27 RIBA-indeterminate donors, 60 RIBA-confirmed donors (48 with and 12 without HCV RNA), and 30 RIBA-negative donors. HCV-specific T-cell responses were identified in 13 (48%) RIBA-indeterminate donors, 33 (55%) RIBA-confirmed donors, and 4 (13%) RIBA-negative controls (p = 0.008 and p < 0.001, respectively). The magnitude of the T-cell response among indeterminate donors was similar to that of RIBA-confirmed donors for all HCV antigens and the specificity of the ELISpot results was confirmed by antigen-specific cytokine production (interleukin-2 and IFN-gamma) in short-term culture supernatants. These findings confirm that approximately half of RIBA-indeterminate donors have resolved a previous HCV infection and suggest that ELISpot might be a useful tool to clarify the status of such donors and help in their counseling and management.

PDF emailed within 0-6 h: $19.90